These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 17363490)

  • 1. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
    Mimeault M; Johansson SL; Vankatraman G; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
    Mol Cancer Ther; 2007 Mar; 6(3):967-78. PubMed ID: 17363490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells.
    Mimeault M; Moore E; Moniaux N; Hénichart JP; Depreux P; Lin MF; Batra SK
    Int J Cancer; 2006 Feb; 118(4):1022-31. PubMed ID: 16108016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
    Mimeault M; Venkatraman G; Johansson SL; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
    Int J Cancer; 2007 Jan; 120(1):160-9. PubMed ID: 17013895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades.
    Mimeault M; Mehta PP; Hauke R; Henichart JP; Depreux P; Lin MF; Batra SK
    Growth Factors; 2007 Dec; 25(6):400-16. PubMed ID: 18365871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.
    Mimeault M; Johansson SL; Henichart JP; Depreux P; Batra SK
    Mol Cancer Ther; 2010 Mar; 9(3):617-30. PubMed ID: 20179163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.
    Lin J; Wu H; Shi H; Pan W; Yu H; Zhu J
    PLoS One; 2013; 8(10):e76169. PubMed ID: 24155892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer.
    Mimeault M; Rachagani S; Muniyan S; Seshacharyulu P; Johansson SL; Datta K; Lin MF; Batra SK
    Oncotarget; 2015 Feb; 6(6):3887-903. PubMed ID: 25682877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer.
    Lin JZ; Hameed I; Xu Z; Yu Y; Ren ZY; Zhu JG
    Oncol Rep; 2018 Oct; 40(4):2242-2250. PubMed ID: 30066906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
    Ikezoe T; Hisatake Y; Takeuchi T; Ohtsuki Y; Yang Y; Said JW; Taguchi H; Koeffler HP
    Cancer Res; 2004 Oct; 64(20):7426-31. PubMed ID: 15492266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antiproliferative and apoptotic effects induced by epidermal growth factor receptor and protein kinase a inhibitors in human prostatic cancer cell lines.
    Mimeault M; Pommery N; Hénichart JP
    Int J Cancer; 2003 Aug; 106(1):116-24. PubMed ID: 12794766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of sonic hedgehog signal pathway enhances antiproliferative effect of EGFR inhibitor in pancreatic cancer cells.
    Hu WG; Liu T; Xiong JX; Wang CY
    Acta Pharmacol Sin; 2007 Aug; 28(8):1224-30. PubMed ID: 17640486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer.
    Salzberg M; Rochlitz C; Morant R; Thalmann G; Pedrazzini A; Roggero E; Schönenberger A; Knuth A; Borner M
    Onkologie; 2007 Jul; 30(7):355-60. PubMed ID: 17596743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carnosol inhibits Hedgehog signaling pathway in both LNCaP and DU145 prostate cancer cell lines.
    Gao H; Song Q; Yang J; Yu S; Zhao J; Yu G
    Cell Mol Biol (Noisy-le-grand); 2017 Aug; 63(8):104-108. PubMed ID: 28886322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer cell growth via the Sonic Hedgehog pathway.
    Datta MW; Hernandez AM; Schlicht MJ; Kahler AJ; DeGueme AM; Dhir R; Shah RB; Farach-Carson C; Barrett A; Datta S
    Mol Cancer; 2006 Mar; 5():9. PubMed ID: 16507112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
    Festuccia C; Gravina GL; Angelucci A; Millimaggi D; Muzi P; Vicentini C; Bologna M
    Int J Cancer; 2005 Jul; 115(4):630-40. PubMed ID: 15700310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.
    Guérin O; Etienne-Grimaldi MC; Monteverde M; Sudaka A; Brunstein MC; Formento P; Lattanzio L; Maffi M; Tonissi F; Ortholan C; Pagès G; Fischel JL; Lo Nigro C; Merlano M; Milano G
    Urol Oncol; 2013 Nov; 31(8):1567-75. PubMed ID: 22608542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer.
    Yano S; Matsuyama H; Hirata H; Inoue R; Matsumoto H; Ohmi C; Miura K; Shirai M; Iizuka N; Naito K
    Oncol Rep; 2006 Jun; 15(6):1453-60. PubMed ID: 16685379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sonic hedgehog and androgen signaling in tumor and stromal compartments drives epithelial-mesenchymal transition in prostate cancer.
    Yamamichi F; Shigemura K; Behnsawy HM; Meligy FY; Huang WC; Li X; Yamanaka K; Hanioka K; Miyake H; Tanaka K; Kawabata M; Shirakawa T; Fujisawa M
    Scand J Urol; 2014 Dec; 48(6):523-32. PubMed ID: 25356787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
    Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
    Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
    Corkery B; Crown J; Clynes M; O'Donovan N
    Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.